Novavax beats first-quarter revenue estimates on vaccine deals strength

Novavax, Inc.

Novavax, Inc.

NVAX

0.00

- Novavax NVAX.O on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine supply and licensing deals helped offset pressure from sagging demand.

First-quarter revenue came in at $139.5 million, topping analysts' estimate of $78.3 million, according to LSEG-compiled data.